Biotricity Inc Stock Price, News & Analysis

Biotricity (OTCQB:BTCY) and B-Secur have announced a significant expansion of their cardiac monitoring platform to include consumer wearables integration. The device-neutral platform, initially launched in early 2025 for ambulatory cardiac monitoring, will now incorporate ECG data from smartwatches, smart rings, and fitness trackers.

The enhanced platform leverages B-Secur's FDA-cleared HeartKey® ECG algorithms to deliver medical-grade accuracy. This advancement enables seamless integration of consumer device data into regulated care pathways, bridging the gap between consumer wearables and clinical care. The initiative aims to address the growing global cardiovascular disease burden, which is projected to triple global costs to $1.8 trillion by 2050.

Biotricity (OTCQB:BTCY) reported strong Q1 FY2026 results, marking a significant milestone with its first-ever positive EBITDA of $333,337. Revenue grew 21% to $3.9 million, with recurring Technology-as-a-Service fees increasing 11.8% to $3.4 million. The company achieved an improved gross margin of 80.5%, up from 73.8% year-over-year.

Net loss significantly decreased to $0.75 million ($0.03 per share), an 80.6% improvement from the previous year. The company's strategic expansion now covers 70% of the US market, with partnerships giving access to 90% of all US hospitals. Biotricity's AI-driven Cardiac Cloud platform, leveraging over 2 trillion beats of anonymized data, is advancing towards FDA clearance.

Biotricity (OTCQB:BTCY), a Technology-as-a-Service healthcare company, will host its Fiscal 2026 First Quarter Financial Results conference call on August 14, 2025, at 4:30 PM ET. The company anticipates reporting continued revenue growth, margin improvements, enhanced operational efficiency, and notably, a shift to positive EBITDA.

CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will lead the presentation and Q&A session. Investors can access the call via toll-free numbers or a webcast, with replay available until August 28, 2025.

Biotricity (OTCQB:BTCY), a Technology-as-a-Service healthcare solutions provider, reported strong financial results for FY2025. The company achieved 14.3% revenue growth to $13.8 million, with significant margin improvement to 76.6% from 69.3% in the previous year.

Key highlights include a 24.5% reduction in operating expenses, negative EBITDA improvement of 63.9% to $3.2 million, and the company's first-ever positive Adjusted EBITDA of $438,260 in Q4-FY25. Recurring Technology Fees grew 12% YOY to $12.6 million, representing over 10.5 times Device Sales revenue. The company secured strategic partnerships with GPOs representing 90% of US hospitals and is pursuing FDA clearance for its AI clinical model.

Biotricity (OTCQB:BTCY), a Technology-as-a-Service healthcare company, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025, at 4:45 PM ET. The company anticipates announcing its best financial performance to date, including improvements in margins, operational efficiency, and a shift to positive adjusted EBITDA.

CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will lead the presentation followed by a Q&A session. The call will be accessible via webcast and toll-free numbers, with replay available until August 1, 2025.

Biotricity (OTCQB: BTCY) has been named one of the Americas' Fastest-Growing Companies 2025 by the Financial Times, achieving remarkable growth of 256.4% between 2020 and 2023. The company, specializing in Technology-as-a-Service for diagnostic and chronic disease management solutions, has demonstrated exceptional performance despite global challenges including the COVID-19 pandemic and supply chain disruptions.

The recognition comes as Biotricity addresses a critical healthcare gap, with over 100 million Americans facing barriers to accessing essential healthcare services. The company's proprietary remote monitoring technologies have particularly impacted high-risk cardiac patients, enabling medical providers to deliver faster interventions both in the U.S. and internationally.

The complete Financial Times report will be published on April 25, 2025, available to U.S. newspaper subscribers and globally on ft.com.

Biotricity (OTCQB:BTCY) has significantly expanded its intellectual property portfolio with 14 new patents, bringing its total to 15 issued patents and 14 pending. The company's latest innovations focus on a breakthrough multi-biometric device platform that can function as both a patch and watch for remote patient monitoring.

The new technology enables simultaneous diagnostic studies through a versatile device with base components that can be transferred between patch and watch form factors. This advancement allows for concurrent diagnostic assessments, such as cardiac and sleep studies, streamlining the patient care process and reducing diagnosis delays.

The expanded patent portfolio reinforces Biotricity's position in remote monitoring, diagnostics, and chronic disease management solutions. The company's Technology-as-a-Service (TaaS) approach aims to improve patient outcomes by enabling earlier detection of health issues while generating revenue through insurance reimbursement.

Biotricity (BTCY) reported strong Q3 FY25 results with revenue growth of 21.7% YOY to $3.6 million. The company achieved significant improvements in key metrics, including gross margins reaching 76.4% (up from 72.9% YOY) and a 56.7% reduction in net loss to $1.32 million.

Recurring Technology Fee revenue, comprising 94% of total revenue, demonstrated robust performance with an 81.4% gross profit percentage. The company successfully reduced SG&A expenses by 20.5% to $2.38 million compared to the previous year. Biotricity achieved positive cash flow on current operating basis for the second consecutive quarter, showing a 114.5% improvement from the prior quarter.

The company's technology is currently utilized across hundreds of centers in 35 states, with a growing focus on hospital networks and AI-driven solutions for remote cardiac care.

Biotricity (OTCQB: BTCY), a Technology-as-a-Service company in remote cardiac monitoring, has announced strong financial performance for Q3-FY25. The company expects to report revenue of $3.6 million, representing a 22% year-over-year growth and an 11% sequential increase from the previous quarter.

The company will achieve positive cash flow for Q3-FY25 on current operating basis (before interest, dividends, and amortization), along with improved gross margins and operating results. This progress stems from their focus on automation, operating efficiency, and financial discipline while leveraging their Biocore suite of products and AI-driven solutions.

The full financial results will be released on February 19th, 2025, followed by a conference call on February 20th at 5:30 PM EST.